title: Clevidipine for severe hypertension in acute heart failure: a VELOCITY trial analysis.
abstract: Acute severe hypertension occurs in approximately 50% of patients with acute heart failure (AHF). Clevidipine, the latest-generation dihydropyridine calcium channel blocker, may be useful in the treatment of this patient population. The Evaluation of the Effect of Ultra-Short-Acting Clevidipine in the Treatment of Patients With Severe Hypertension (VELOCITY) trial enrolled 126 patients with systolic blood pressure (SBP) >180 mm Hg for treatment with clevidipine to a patient-specific prespecified initial target range (ITR) of SBP to be achieved within 30 minutes. Of the enrolled patients, 19 had AHF on presentation. Primary end points were the percentage in whom ITR was achieved within 30 minutes and the number whose SBP was below the ITR after 3 minutes of clevidipine infusion. Among the 19 AHF patients in VELOCITY, median time to ITR was 11.3 minutes (95% confidence interval, 7-19). ITR was reached in most patients (94%) within 30 minutes. No patient had hypotension below the ITR, and heart rate remained stable. At 18 hours, 16 of 19 patients had received continuous clevidipine infusion, and their SBP was reduced by mean of 50 mm Hg (25%) from baseline. There were no treatment-related adverse events or adverse events that led to clevidipine discontinuation. Clevidipine safely decreases SBP in AHF and does not cause unexpected hypotension. The results of this post hoc subgroup analysis suggest that clevidipine is safe, well tolerated, and efficacious in AHF patients with hypertension.
authors.affiliation: Department of Emergency Medicine, Cleveland Clinic, Cleveland, OH 44195-0001, USA. peacocw@ccf.org
authors.forename: Frank  W
authors.initials: F
authors.lastname: Peacock
authors.forename: Joseph
authors.initials: J
authors.lastname: Varon
authors.forename: Ramin
authors.initials: R
authors.lastname: Ebrahimi
authors.forename: Lala
authors.initials: L
authors.lastname: Dunbar
authors.forename: Charles V
authors.initials: CV
authors.lastname: Pollack
mesh_terms: D000208:Acute Disease; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D016001:Confidence Intervals; D004095:Dihydropyridines / Q000627:therapeutic use; D005260:Female; D006305:Health Status Indicators; D006333:Heart Failure / Q000150:complications*; D006339:Heart Rate; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000000981:diagnostic imaging / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011725:Pyridines / Q000627:therapeutic use*; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014463:Ultrasonography
chemical_list: D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D004095:Dihydropyridines; D011725:Pyridines; C118563:clevidipine; C038806:1,4-dihydropyridine